anti-CD79b CAR T-cell therapy (MD Anderson)

This investigational CAR T-cell therapy, developed at The University of Texas MD Anderson Cancer Center, is designed to treat B-cell malignancies, specifically targeting patients with relapsed or refractory B-cell lymphomas who may have failed CD19-targeted therapies. The chimeric antigen receptor (CAR) targets CD79b, a protein that is part of the B-cell receptor complex and is widely expressed across various B-cell lymphomas, including cases where CD19 expression has been lost. The construct features a novel anti-CD79b monoclonal antibody-derived single-chain variable fragment (scFv), a CD8α hinge and transmembrane domain, an OX40 co-stimulatory domain, and a CD3ζ signaling domain. Preclinical evaluations demonstrated that these CAR T cells exhibit robust cytotoxic activity against both CD19-positive and CD19-negative lymphoma cell lines, leading to the initiation of Phase 1 clinical trials to assess safety and efficacy in human subjects.

Other names

anti-CD79b CAR T-cellanti-CD-79b CAR T-cellanti-CD 79b CAR T-cellCD79b-targeted CAR T-cell therapyCD-79b-targeted CAR T-cell therapyCD 79b-targeted CAR T-cell therapyCD79b CAR-TCD-79b CAR-TCD 79b CAR-T